A carregar...
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
With an explosion of available treatments for metastatic renal cell carcinoma (mRCC) in recent years, it is important to recognize that approved targeted therapies fall broadly into only two mechanistic categories. The first category, vascular endothelial growth factor (VEGF)-directed therapies, inc...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3253822/ https://ncbi.nlm.nih.gov/pubmed/21484496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-011-0172-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|